Related Experiment Video
Updated: May 9, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment
Loris Roncali1,2,3, François Hindré2,4, Edouard Samarut3,5
1Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela; E-15782 Santiago de Compostela, Spain.
Abstract:
Glioblastoma (GB) is the most aggressive malignancy of the central nervous system. Despite two decades of intensive research since the establishment of the standard of care, emerging strategies have yet to produce consistent satisfactory outcomes. Because of its specific localisation and intricate characteristics, GB is a uniquely regulated solid tumour with a strong resistance to therapy. Advances in targeted radionuclide therapy (TRT), particularly with the introduction of a-emitting radionuclides, have unveiled potential avenues for the management of GB. Recent preclinical and clinical studies underscored promising advancements for targeted-α-therapy (TAT), but these therapeutic approaches exhibit a vast design heterogeneity, encompassing diverse radionuclides, vectors, target molecules, and administration modalities. This review seeks to critically assess the therapeutic landscape of GB through the perspective of TAT. Here, the focus is made on the advancements and limitations of in vivo explorations, pilot studies, and clinical trials, to determine the best directions for future investigations. In doing so, we hope to identify existing challenges and draw insights that might pave the way towards a more effective therapeutic approach.
Insights
Targeted alpha-therapy (TAT) shows promise for glioblastoma (GB) treatment, offering new avenues beyond standard care. This review critically examines TAT
Area of Science:
- Neuro-oncology
- Radiopharmaceutical therapy
- Cancer research
Background:
- Glioblastoma (GB) is the most aggressive central nervous system malignancy.
- Current treatments face challenges due to GB's resistance and complex characteristics.
- Standard care for glioblastoma has yielded limited improvements over two decades.
Purpose of the Study:
- To critically assess the therapeutic landscape of glioblastoma (GB) using targeted alpha-therapy (TAT).
- To review advancements and limitations of in vivo explorations, pilot studies, and clinical trials for TAT in GB.
- To identify challenges and guide future research directions for more effective glioblastoma treatment.
Main Methods:
- Comprehensive review of preclinical and clinical studies on targeted alpha-therapy (TAT) for glioblastoma (GB).
- Analysis of diverse TAT design elements, including radionuclides, vectors, target molecules, and administration routes.
- Evaluation of in vivo data, pilot studies, and clinical trial outcomes.
Main Results:
- Targeted radionuclide therapy (TRT), especially TAT, presents promising avenues for glioblastoma management.
- TAT approaches show significant advancements but exhibit considerable heterogeneity in design and application.
- Existing studies highlight both potential benefits and limitations of current TAT strategies for glioblastoma.
Conclusions:
- Targeted alpha-therapy (TAT) offers a potential breakthrough for glioblastoma treatment.
- Further research is needed to optimize TAT design and overcome therapeutic resistance.
- Addressing current challenges in TAT development is crucial for advancing glioblastoma therapy.
